Ali Health (00241) rose more than 8% and rose 16% in 2 trading days. As of press release, it had risen 8.25% to HK$3.28, with a turnover of HK$71.01 million.
The Zhitong Finance App learned that Ali Health (00241) rose more than 8% and rose 16% in 2 trading days. As of press release, it had risen 8.25% to HK$3.28, with a turnover of HK$71.01 million.
According to the news, Alibaba Health recently announced that on November 28, 2023, the company entered into a share purchase agreement with the seller (Taobao Holdings Co., Ltd., a direct wholly-owned subsidiary of Alibaba Holdings). The company agreed to purchase all of the target company's issued share capital, subject to the terms and conditions of the share purchase agreement. The consideration payable by the company to the seller at the time of delivery is HK$13.512 billion, which will be paid through the following methods: the company issues 2,558 billion shares of consideration to the seller (and/or its nominee) at an issue price of HK$4.50 per share at the time of delivery; and the company pays the seller an equivalent of HK$2 billion in cash at the time of delivery. In the event of a share split, share merger, dividend or similar event relating to the company's share capital prior to delivery, the issue price may be adjusted.
According to the announcement, all preconditions for the proposed acquisition under the share purchase agreement have been fulfilled, and the delivery was carried out in accordance with the terms and conditions of the share purchase agreement on January 17, 2024. A total of 2,558 billion shares of consideration have been distributed and issued to the seller at an issue price of HK$4.50 per share in accordance with the terms and conditions of the share purchase agreement, and the target company has become a wholly-owned subsidiary of the company.